The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Basit Öğe Kaydı
dc.authorid0000-0002-3353-344X
dc.authorid0000-0001-6235-7927
dc.authorid0000-0001-7411-1705
dc.authorid0000-0001-5147-4431
dc.authorid0000-0001-7680-4142
dc.authorscopusid57195492869
dc.authorscopusid57192957882
dc.authorscopusid57205608177
dc.authorscopusid56357909800
dc.authorscopusid26039488700
dc.authorscopusid57217738098
dc.authorscopusid57205578251
dc.authorwosidCaner, Burcu/AAE-8549-2022
dc.authorwosidgülmez, ahmet/ABI-8218-2020
dc.authorwosidYücel, Şebnem/AAY-6737-2021
dc.contributor.authorHizal, Mutlu
dc.contributor.authorBilgin, Burak
dc.contributor.authorPaksoy, Nail
dc.contributor.authorAcıkgöz, Özgür
dc.contributor.authorSezer, Ahmet
dc.contributor.authorGürbüz, Mustafa
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorİriağaç, Yakup
dc.date.accessioned2022-05-11T14:40:57Z
dc.date.available2022-05-11T14:40:57Z
dc.date.issued2021
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalı
dc.description.abstractIntroduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3-4 adverse events were seen in 11.7% of the patients. Conclusion Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile.
dc.identifier.doi10.1007/s00432-021-03748-7
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.pmid34331582
dc.identifier.scopus2-s2.0-85111543488
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1007/s00432-021-03748-7
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8987
dc.identifier.wosWOS:000679766900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorİriağaç, Yakup
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofJournal of Cancer Research and Clinical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectOsimertinib
dc.subjectNon-small cell lung cancer
dc.subjectEGFR
dc.subjectT790M
dc.subjectSecond line
dc.subjectChemotherapy
dc.subjectTherapy
dc.subjectProgram
dc.subjectTime
dc.titleThe real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
8987.pdf
Boyut:
535.19 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu